Len Blavatnik MediWound jumps on reports of acquisition talks

The Israeli burns and wound management company has hired an investment bank that specializes in mergers and acquisitions.

medical research image: Shutterstock Israeli blood analysis co PixCell wins €2.5m EU grant

PixCell's HemoScreen performs a complete blood count within 5 minutes enabling physicians to diagnose and treat their patients during a single visit.

Nasdaq Photo: Reuters Drug release co PolyPid sets terms for $75m Nasdaq IPO

The offering by the Israeli company, scheduled for March 23, is planned at a $370 million company value.

Teva CFO Michael McClellan Photo: Company website Teva scraps NTE integrated R&D project

CFO Michael McClellan: Nothing really ever came out of NTE so we terminated it.

David Silver  photo: Eitan Mehulal & Sadot Teva patent exec joins law firm Eitan Mehulal & Sadot

David Silver was until recently Senior IP Director and Chief Scientist in Teva's Intellectual Property Department. 

Kare Schultz Photo: PR Teva terminates Heptares migraine drug development rights

Teva is returning the rights to commercialize the small molecule gene-related peptide CGRP antagonist HTL0022562 as part of its streamlining plan.

medical research image: Shutterstock Hitachi Chemical licenses stem cell tech from Israel's Accellta

Haifa-based Accellta has developed technology for high speed mass culturing of stem cells.

Uri Geiger and Mori Arkin Photos: PR and Jonathan Bloom Accelmed fund makes 250% on Cogentix exit

Cogentix, sold to Canadian company Laborie for $242 million, is the biggest success so far for Accelmed's investment model.

Lab Technician.  Photo: Reuters Making good bacteria more resilient

Israeli microbiome company MyBiotics Pharma's MyCrobe technology aims to let good bacteria live longer in the gut.

Dr. Stefan Oschmann  photo: Shlomi Yosef Merck KGaA showing Teva the way?

Merck CEO Dr. Stefan Oschmann is reluctant to comment on Teva, but comparisons are inevitable.

New Reality Solutions Photo: Eyal Yitzhar New Reality Solutions makes first Israel investments

NRS believes that biological developments for improving agriculture can lead to a breakthrough in understanding biological mechanisms in people.

Treatment at Alyn Hospital ALYNnovation: 'Impossible' is not in our vocabulary

ALYNnovation takes medical innovations developed at the ALYN pediatric rehabilitation hospital out of the hospital so that all children can benefit from them.

Freddy Zinger Photo: Eyal Yitzhar Former Teva exec sets up Galilee incubator

Freddy Zinger does not rule out buying Teva Migada in Kiryat Shmona, the company he founded.

Kare Schultz Photo: PR Teva share price up 75% since Schultz became CEO

Kare Schultz has stabilized the ship but faces enormous opposition to his streamlining plan.

Teva Photo: Reuters Teva: Healthy business, sick share

Every change in Teva's business is amplified in its share price.

Prof Eyal Winter  photo: private Israeli drug exploration partnership can save Teva

Teva, Israel's universities and the state should join forces to find and develop new drugs, says Prof. Eyal Winter.

Teva workers demonstrate  photo: courtesy Histadrut Economic damage from Teva's cutbacks will mainly be local

Teva's contribution to Israel's tax revenues has been virtually zero.

Teva Photo: Tamar Matsafi Most Teva Israel layoffs expected at Petah Tikva HQ

As Teva workers await the axe, one tells "Globes" that he fears he will be shortchanged while outgoing CSO Michael Hayden gets $2.5 million by the end of 2018.

Teva Photo: Tamar Matsafi "Teva's senior execs should pay back excessive salaries"

Former Teva chairman Meir Heth believes the company's top executives are responsible for the current situation.

Teva Photo: Tamar Matsafi US hedge funds reduce Teva exposure

Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.

Dalton Conley Photo: PR "Genetic inequality is increasing"

Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.

Teva  photo: Reuters Poalim IBI: Teva must raise capital

Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.

Prof. Zelig Eshar Photo: Shlomi Yosef Israeli professors fight for Kite Pharma sale spoils

Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

Prof Michal Schwartz photo: Rami Zarnegar "Lady Globes" Woman of the Year: Prof. Michal Schwartz

The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018